$272 Million is the total value of Corriente Advisors, LLC's 10 reported holdings in Q1 2021. The portfolio turnover from Q4 2020 to Q1 2021 was 89.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MAXR | Buy | MAXAR TECHNOLOGIES INC | $100,223,000 | +3.9% | 2,650,000 | +6.0% | 36.90% | +60.7% |
| REPL | Sell | REPLIMUNE GROUP INC | $32,798,000 | -30.4% | 1,075,000 | -13.0% | 12.08% | +7.7% |
| CUE | Buy | CUE BIOPHARMA INC | $31,098,000 | +29.8% | 2,549,031 | +33.1% | 11.45% | +100.8% |
| CRDF | Buy | CARDIFF ONCOLOGY INC | $25,793,000 | -28.3% | 2,785,410 | +39.3% | 9.50% | +10.9% |
| TDY | New | TELEDYNE TECHNOLOGIES INC | $22,751,000 | – | 55,000 | +100.0% | 8.38% | – |
| TFFP | Buy | TFF PHARMACEUTICALS INC | $21,246,000 | +9.9% | 1,565,682 | +16.0% | 7.82% | +70.0% |
| FB | New | FACEBOOK INCcl a | $14,727,000 | – | 50,000 | +100.0% | 5.42% | – |
| LTRN | New | LANTERN PHARMA INC | $12,948,000 | – | 713,806 | +100.0% | 4.77% | – |
| DMAC | Buy | DIAMEDICA THERAPEUTICS INC | $7,963,000 | -2.7% | 870,228 | +7.8% | 2.93% | +50.5% |
| EYPT | New | EYEPOINT PHARMACEUTICALS INC | $2,032,000 | – | 200,000 | +100.0% | 0.75% | – |
| QS | Exit | QUANTUMSCAPE CORP | $0 | – | -1,000 | -100.0% | -0.02% | – |
| OCUL | Exit | OCULAR THERAPEUTIX INC | $0 | – | -53,934 | -100.0% | -0.27% | – |
| ONCR | Exit | ONCORUS INC | $0 | – | -78,043 | -100.0% | -0.60% | – |
| NXE | Exit | NEXGEN ENERGY LTD | $0 | – | -1,000,000 | -100.0% | -0.66% | – |
| KTOS | Exit | KRATOS DEFENSE & SEC SOLUTIO | $0 | – | -200,014 | -100.0% | -1.31% | – |
| CNCE | Exit | CONCERT PHARMACEUTICALS INC | $0 | – | -680,000 | -100.0% | -2.05% | – |
| CRIS | Exit | CURIS INC | $0 | – | -1,100,000 | -100.0% | -2.14% | – |
| CMPS | Exit | COMPASS PATHWAYS PLCsponsored ads | $0 | – | -190,000 | -100.0% | -2.16% | – |
| Exit | APTOSE BIOSCIENCES INC | $0 | – | -2,900,000 | -100.0% | -3.02% | – | |
| FEYE | Exit | FIREEYE INC | $0 | – | -690,000 | -100.0% | -3.79% | – |
| GPRO | Exit | GOPRO INCcl a | $0 | – | -3,350,000 | -100.0% | -6.60% | – |
| CCJ | Exit | CAMECO CORP | $0 | – | -2,177,086 | -100.0% | -6.94% | – |
| RETA | Exit | REATA PHARMACEUTICALS INCcl a | $0 | – | -525,000 | -100.0% | -15.45% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-05-18
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CUE BIOPHARMA INC | 8 | Q3 2021 | 26.7% |
| MAXAR TECHNOLOGIES INC | 7 | Q2 2021 | 41.3% |
| REATA PHARMACEUTICALS INC | 6 | Q2 2021 | 29.6% |
| REPLIMUNE GROUP INC | 5 | Q2 2021 | 12.1% |
| APTOSE BIOSCIENCES INC | 5 | Q4 2020 | 18.7% |
| CARDIFF ONCOLOGY INC | 5 | Q2 2021 | 9.5% |
| DIAMEDICA THERAPEUTICS INC | 5 | Q2 2021 | 2.9% |
| TFF PHARMACEUTICALS INC | 4 | Q3 2021 | 15.2% |
| INVESCO QQQ TR | 3 | Q3 2022 | 94.7% |
| LANTERN PHARMA INC | 3 | Q3 2021 | 13.5% |
View Corriente Advisors, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Cardiff Oncology, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| Cue Biopharma, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| TFF Pharmaceuticals, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| CATABASIS PHARMACEUTICALS INCSold out | February 16, 2021 | 0 | 0.0% |
| NAUTILUS, INC.Sold out | February 16, 2021 | 0 | 0.0% |
| Maxar Technologies Inc. | November 26, 2019 | 2,920,750 | 4.9% |
| CATABASIS PHARMACEUTICALS INC | February 23, 2018 | 1,692,899 | 7.3% |
| NEUROLOGIX INC/DE | February 14, 2011 | 16,858,224 | 37.7% |
| AMERICAN VANTAGE COMPANIESSold out | February 16, 2010 | 0 | 0.0% |
| AspenBio Pharma, Inc.Sold out | February 16, 2010 | 0 | 0.0% |
View Corriente Advisors, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-09 |
| 13F-HR | 2023-05-10 |
| 13F-HR | 2023-02-15 |
| 13F-HR | 2022-11-15 |
| 13F-HR | 2022-08-16 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-15 |
| SC 13G/A | 2022-02-14 |
View Corriente Advisors, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.